Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875307 | 1.00 | HSD17B10 (0.37) | HSD17B10MEN1KMT2AESR1BUB1 | |
| SCHEMBL877125 | 0.88 | MAPK1 (0.40) | HSD17B10MEN1KMT2ABUB1DDB1 | |
| SCHEMBL877124 | 0.88 | MAPK1 (0.40) | HSD17B10MEN1KMT2ABUB1DDB1 | |
| SCHEMBL876133 | 0.85 | PTPN1 (0.39) | MEN1KMT2ABUB1DDB1CRBN | |
| SCHEMBL8288614 | 0.85 | PTPN1 (0.39) | MEN1KMT2ABUB1DDB1CRBN | |
| SCHEMBL6244524 | 0.85 | HSD17B10 (0.37) | HSD17B10MEN1KMT2ABUB1NR1H2 | |
| SCHEMBL21367151 | 0.80 | MEN1 (0.33) | HSD17B10MEN1KMT2AESR1BUB1 | |
| SCHEMBL28397904 | 0.78 | ELANE (0.44) | — | |
| SCHEMBL5201612 | 0.77 | MEN1 (0.33) | HSD17B10MEN1KMT2ABUB1DDB1 | |
| SCHEMBL5201608 | 0.77 | MEN1 (0.33) | HSD17B10MEN1KMT2ABUB1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-18 | — | — | US | disclosed |
| US-20180099949-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3140296-B1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9873679-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3140296-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Bristol-Myers Squibb Company (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| WO-2015171722-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012040242-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | HSD17B10 1463/4885MEN1 4071/4885KMT2A 4319/4885 |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | HSD17B10 2966/4885MEN1 4795/4885KMT2A 1733/4885 |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | HSD17B10 1463/4885MEN1 4071/4885KMT2A 4319/4885 |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | HSD17B10 1463/4885MEN1 4071/4885KMT2A 4319/4885 |
| US-20180099949-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | HSD17B10 1463/4885MEN1 4071/4885KMT2A 4319/4885 |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | HSD17B10 1463/4885MEN1 4071/4885KMT2A 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.